Fosamax and Osteonecrosis of the Jaw: Causation and Medical Literature on Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information dissemination has long provided a foundation for public understanding of medication risks and benefits. Within this broad context, the communication of adverse drug effects has historically focused on common, well-documented outcomes, such as gastrointestinal or cardiovascular events. This established framework, however, is now being extended to address more specialized and less frequent, yet serious, complications associated with long-term pharmaceutical use. One such area of emerging concern involves the relationship between bisphosphonate therapy, specifically Fosamax, and the development of osteonecrosis of the jaw. The transition from general health awareness to this specific risk requires a careful pivot, moving from broad educational principles to a focused examination of exposure patterns. In the occupational setting, this concern takes on a distinct dimension. Healthcare professionals, particularly those in dentistry and oral surgery, may encounter patients with a history of Fosamax use, necessitating a heightened awareness of potential jaw complications. Furthermore, workers in pharmaceutical manufacturing or distribution may face unique exposure scenarios that warrant separate consideration. Thus, the general health context serves as a necessary precursor, enabling a more targeted inquiry into how occupational exposure to Fosamax might correlate with the risk of osteonecrosis of the jaw, without yet delving into specific mechanistic pathways.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general health context, we now focus specifically on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Clinical Presentation and Diagnosis of ONJ

The clinical presentation of ONJ involves areas of exposed bone in the maxillofacial region that persist for more than eight weeks, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as metastatic disease or osteoradionecrosis. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding points to the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental procedures or infection. Multiscale characterization of jawbone tissue has provided comprehensive information that helps understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's unique anatomy, with its thin mucosa and high mechanical load from chewing, may make it particularly vulnerable to compromised blood supply and delayed healing when osteoclast function is suppressed.

Risk Factors and Epidemiology

Risk factors for developing ONJ while on Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Timeline and Causation Considerations

The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, though a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that not all jaw symptoms in bisphosphonate users are attributable to ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4), which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset, excluding other potential causes such as cancer or radiation therapy, and evaluating the presence of known risk factors. The risk of ONJ is dose- and duration-dependent, with higher risk after prolonged use. For patients who develop ONJ, management typically includes discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further invasive dental procedures. The condition may resolve after stopping the drug, but some patients experience persistent symptoms. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly with longer duration of use and in the presence of additional risk factors. The prescribing information provides warnings and management recommendations, but the absolute risk remains low. Patients and healthcare providers should weigh the benefits of osteoporosis treatment against the rare but serious risk of ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. It is a recognized adverse effect of bisphosphonate use, including Fosamax, due to suppression of bone remodeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of Fosamax use increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in Fosamax users?

Absolute risks are low, approximately 0.05% after 5 years of use. However, risk increases with duration: threefold higher after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What should I do if I develop jaw symptoms while taking Fosamax?

Consult your healthcare provider immediately. They may recommend discontinuing Fosamax, especially before invasive dental procedures. Management includes conservative debridement, infection control, and avoiding further dental surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.